Erlotinib therapy in a patient with non-small-cell lung cancer and brain metastases
Erlotinib therapy in a patient with non-small-cell lung cancer and brain metastases
复制标题
DOI：
10.1007/s11060-008-9623-4
复制
发表时间：
2008-10-01
影响因子：
3.9
通讯作者：
Pitini, Vincenzo V.
中科院分区：
文献类型：
--
作者：
Altavilla, Giuseppe;Arrigo, Carmela;Pitini, Vincenzo V.
脑转移是非小细胞肺癌的常见发生和死亡的主要原因，几乎没有全身治疗选择。虽然靶向表皮生长因子受体相关酪氨酸激酶与厄洛替尼和吉非替尼在一些患者中产生持久的反应，但这些药物对脑转移的活性记录很少。特别是，迄今为止很少有报道厄洛替尼在这种情况下的活性。在这里，我们报告的情况下，男性意大利吸烟者与肺腺癌的肺癌和脑转移都有反应厄洛替尼。
Brain metastases are a common occurrence and a major cause of mortality in non-small-cell lung cancer, with few systemic treatment options. Although targeting epidermal growth factor receptor-associated tyrosine kinase with erlotinib and gefitinib results in durable responses in some patients, the activity of these drugs against brain metastases has been poorly documented. In particular, few reports have so far reported the activity of erlotinib in this setting. Here we report the case of a male Italian smoker with an adeno-carcinoma of the lung whose lung cancer and brain metastases have both responded to erlotinib.